Colorado's Bipartisan Bid to Study Ibogaine for Veterans' Mental Health Hits Budget Wall

A bipartisan push in Colorado aims to fund research into ibogaine, a psychedelic drug with potential to treat mental health issues and addiction. The effort comes as veterans’ groups and lawmakers seek new solutions for rising suicide rates and opioid dependency among former service members. Meanwhile, President Donald Trump has also ordered federal research into the substance, though its legal status remains a hurdle. Ibogaine is a naturally occurring psychedelic found in the iboga shrub, traditionally used by the Fang people of Central Africa in spiritual ceremonies. In the U.S., it is classified as a Schedule 1 drug, making it illegal to possess or distribute without strict research approval.

A 2022 study suggested ibogaine could help treat opioid addiction, but the drug has also been linked to serious side effects, including fatal heart complications. Despite the risks, veterans’ organisations like Disabled American Veterans are backing further research, citing alarming rates of suicide and untreated mental illness among former military personnel. In Colorado, House Bill 26-1325 proposes a state-funded pilot program to explore ibogaine’s therapeutic potential. The bill has bipartisan support, including from lawmakers with military backgrounds, and Governor Jared Polis has expressed approval. However, the measure is currently stalled due to a state budget shortfall. At the federal level, Trump recently issued an executive order directing research into ibogaine for opiate and substance abuse treatment. Yet, executive orders can be easily reversed by future administrations, leaving state-level legislation as the more stable path for long-term change. The Make America Healthy Again movement has also rallied behind the drug, adding public pressure for further study.

The Colorado bill remains on hold until funding becomes available, but its backers continue to push for approval. If passed, the pilot program could provide critical data on ibogaine’s safety and effectiveness. For now, the drug’s legal status and financial constraints keep research efforts in limbo.